1. Introduction {#sec1-biomolecules-09-00650}
===============

Seventy years ago, Katz detected the inward rectification phenomenon for the first time \[[@B1-biomolecules-09-00650]\]. Its unexpected property of conducting larger inward than outward potassium currents at similar deviations from the potassium equilibrium potential was unprecedented at that time. During the following decades, the understanding of inward rectifier channels was established further, stimulated by biophysical analysis and cloning of K~IR~ genes. Inward rectifying channels---unlike voltage-gated potassium channels (K~v~) which open in response to alterations in transmembrane electrostatic potential \[[@B2-biomolecules-09-00650],[@B3-biomolecules-09-00650]\]---are primarily gated by intracellular substances (e.g., polyamines and Mg^2+^). Spermine and spermidine---two polyamines for which micromolar concentrations are sufficient to reach physiological effective levels---cause stronger block of the outward current than Mg^2+^. The underlying molecular mechanism of rectification was first explained by Lopatin in 1994 \[[@B3-biomolecules-09-00650]\]. Polyamines enter the channel pore from the cytoplasmic side and subsequently interact with six specific residues (i.e., K~IR~2.1 E224, D259, E299, F254, D255 and D172) \[[@B4-biomolecules-09-00650]\] in the transmembrane pore domain and its cytosolic pore extension. A similar mechanism of pore-blocking is caused by Mg^2+^, but weaker.

The inward rectifier channel family consists of strong and weak rectifiers. Strong rectifiers, e.g., K~IR~2 and K~IR~3, are often expressed in excitable cells such as neuronal or muscle cells. Their rectifying properties enable cells to conserve K^+^ during action potential formation and facilitate K^+^ entry upon cell hyperpolarization. In addition, they contribute to repolarization and stabilization of the resting membrane potential. For example, application of 10 µM barium, at that concentration rather specific for K~IR~2 channel inhibition, lengthened the action potential of guinea-pig papillary muscle preparations by 20 ms \[[@B5-biomolecules-09-00650]\]. In the heart, K~IR~2 is strongly expressed in the ventricles and less in the atrioventricular node (AVN) \[[@B6-biomolecules-09-00650]\]; K~IR~3 is mainly expressed in the atrium with much lower levels in the ventricle. Weak rectifier channels, e.g., K~IR~1, K~IR~4, and K~IR~5, are mainly associated with potassium homeostasis and often regulate extracellular potassium concentrations to allow functioning of several ion (co)transporters.

K~IR~ channels are encoded by *KCNJ* genes. Various diseases associate with mutations in *KCNJ* genes. The aim of this review is to correlate disease associated mutations causing aberrant inward rectifier channel trafficking with protein domains important for trafficking by means of channel alignment, and finally to put mutational changes in a structural framework.

2. Classification, Structure, and Expression {#sec2-biomolecules-09-00650}
============================================

The K~IR~ family is divided into seven subfamilies (K~IR~1-7) according to their amino-acid homology \[[@B4-biomolecules-09-00650]\]. The sequence homology is 40% between subfamilies and rises to 70% within some subfamilies. The structural common features of these channels are that the channel pore is formed by a tetramer of subunits, most often homotetramers ([Figure 1](#biomolecules-09-00650-f001){ref-type="fig"}). Each subunit has two transmembrane domains (M1 and M2) which are separated by a pore-loop that contains the GYG (or GFG) potassium selectivity filter motif located close to the extracellular side of the membrane. Pore-loop stability depends strongly on one negatively and one positively charged residue, E138 and R148 respectively in K~IR~2.1 \[[@B7-biomolecules-09-00650]\]. There is a relatively short N-terminus linked to M1 and a longer C-terminus linked to M2 which form the characteristic cytoplasmic extended pore domain (CTD). Despite their structural similarities, the K~IR~ subfamilies also display divergent properties, e.g., sensitivity to extracellular Ba^2+^ or the response to regulatory signals.

All K~IR~ family members have a widespread expression pattern \[[@B4-biomolecules-09-00650]\]. Neural tissues strongly express K~IR~2, K~IR~3, K~IR~4, and K~IR~5. Kidneys show high expression of K~IR~4, K~IR~5, and K~IR~6, whereas pancreatic tissue highly expresses K~IR~5 and K~IR~6. The retina shows profound expression of K~IR~7. The heart displays strong expression of K~IR~2, K~IR~3 and K~IR~6. K~IR~2 subfamily-members form the classical I~K1~ current in working ventricular and atrial cardiomyocytes, where they contribute to repolarization and resting membrane potential stability. K~IR~3 (I~KAch~) members are strongly expressed in the nodal tissues of the heart, where they are involved in heart rate regulation \[[@B8-biomolecules-09-00650]\]. Further, they are widely expressed in the brain where they have numerous neurological functions \[[@B9-biomolecules-09-00650]\]. K~IR~6 channels form octamers with the ATP/ADP sensing SUR subunits and couple cellular metabolic status to cardiac repolarization strength.

3. Channel Trafficking {#sec3-biomolecules-09-00650}
======================

Following their translation in the endoplasmic reticulum (ER), correctly folded K~IR~ channels are transported to the plasma membrane, a process known as forward trafficking, where they exert their main biological role ([Figure 2](#biomolecules-09-00650-f002){ref-type="fig"}). Upon removal from the plasma membrane, channel proteins can enter the degradation pathway in a process named backward trafficking. In addition, K~IR~ channels can enter several recycling pathways. Each of these processes is well regulated and depends mainly on specific trafficking motifs in the channels primary sequence in concert with specific interacting proteins that direct and/or support subsequent trafficking steps. Incorrectly folded proteins will enter the endoplasmic-reticulum-associated protein degradation pathway.

ER-export signals have been determined in several K~IR~ channels \[[@B10-biomolecules-09-00650],[@B11-biomolecules-09-00650],[@B12-biomolecules-09-00650],[@B13-biomolecules-09-00650]\], see also [Section 5.3](#sec5dot3-biomolecules-09-00650){ref-type="sec"}, with homology between subfamily members (e.g., FCYENE in K~IR~2.x channels), although not always among other K~IR~ family members. Not all K~IR~ members possess an ER-export signal, and some might even restrict forward trafficking or stimulate lysosomal breakdown when part of a heteromeric channel, as seen for K~IR~3.3 \[[@B12-biomolecules-09-00650]\]. Other channels even have ER-retention signals that only become masked upon proper channel assembly, as seen for the K~IR~6 family \[[@B13-biomolecules-09-00650]\].

Trans-Golgi transport of several K~IR~ channels has been demonstrated to depend on interaction with Golgin tethers that reside in the trans-Golgi network. For example, Golgin-160 interacts with the C-terminal domain of K~IR~1.1 channels which results in increased forward trafficking and an increase in K~IR~1.1 currents \[[@B14-biomolecules-09-00650]\]. In a similar fashion, Golgin-97 was shown to interact with the C-terminus of K~IR~2.1 and promotes transport to the Golgi-export sites \[[@B15-biomolecules-09-00650]\]. Golgi-export signals have been characterized in a few K~IR~ channels \[[@B16-biomolecules-09-00650],[@B17-biomolecules-09-00650]\]. By a combination of cytoplasmic N- and C-terminal domains, a so-called Golgi-export signal patch is formed that interacts with the AP-1 clathrin adaptor protein.

Protein motifs involved in backward trafficking have been studied less. K~IR~1.1 internalization depends on clathrin-dynamin mediated endocytosis which involved N375 in the K~IR~1.1 putative internalization motif NPN \[[@B18-biomolecules-09-00650]\]. Internalized K~IR~1.1 channels depend on CORVET and ESCRT protein complexes for subsequent trafficking to the early endosome and the multivesicular body that eventually fuses with the lysosome, respectively \[[@B19-biomolecules-09-00650]\]. K~IR~2.1 channels are regulated by the ESCRT machinery also \[[@B20-biomolecules-09-00650]\]. It was demonstrated, by a pharmacological approach, that K~IR~2.1 degradation also depends on clathrin mediated endocytosis and lysosomal activity, and their inhibition resulted in enhanced I~K1~ currents \[[@B21-biomolecules-09-00650],[@B22-biomolecules-09-00650]\]. The TPVT motif of the K~IR~5.1 channel protein binds the Nedd4-2 E3 ubiquitin ligase. In K~IR~5.1/K~IR~4.1 heteromeric complexes, this was suggested to result in ubiquitination and subsequent degradation of K~IR~4.1 in the proteasome \[[@B23-biomolecules-09-00650]\].

Finally, trafficking, anchoring and plasma membrane localization of K~IR~ channels is regulated by their interaction with scaffolding proteins. The C-terminal K~IR~2.2 SEI PDZ-binding domain interacts with SAP97, PSD-95, Chapsyn-110, SAP102, CASK, Dlg2, Dlg3, Pals2, Veli1, Veli3, Mint1, and abLIM from rat brain lysates, and SAP97, CASK, Veli-3, and Mint1 from rat heart lysates \[[@B24-biomolecules-09-00650],[@B25-biomolecules-09-00650],[@B26-biomolecules-09-00650]\]. Additionally, interactions between syntrophins, dystrobrevins and the K~IR~2.2 PDZ domain were shown by these authors. K~IR~2.1 and K~IR~2.3 also interact with SAP97 in the heart. Using an NMR approach, it was found that additional residues close to the K~IR~2.1 PDZ domain were involved in PSD-95 interaction \[[@B27-biomolecules-09-00650]\]. Furthermore, PSD-95 interacts with K~IR~4.1 and K~IR~5.1 in the optic nerve and brain, and PSD-95 interaction is essential for K~IR~5.1 expression at the plasma membrane of HEK293 cells \[[@B28-biomolecules-09-00650],[@B29-biomolecules-09-00650]\]. The C-terminal PDZ-binding motif SNV interacts with PSD-95, and K~IR~4.1 mediated current density more than doubled upon PSD-95 cotransfection in HEK293 cells, and increased even threefold upon SAP97 cotransfection \[[@B30-biomolecules-09-00650]\]. Upon silencing of SAP97, the I~K1~ current decreased due to reduced plasma membrane expression of K~IR~2.1 and K~IR~2.2 ion channels \[[@B31-biomolecules-09-00650]\]. Residues 307--326 of K~IR~2.1 are involved in interactions with the actin binding protein filamin A. Interestingly, these interactions are unaffected by the Andersen--Tawil deletion Δ314/315 \[[@B32-biomolecules-09-00650]\]. In arterial smooth muscle cells, filamin A and K~IR~2.1 colocalize in specific regions of the plasma membrane. Although filamin A is not essential for K~IR~2.1 trafficking to the plasma membrane, its absence reduces the amount of K~IR~2.1 channels present at the plasma membrane \[[@B32-biomolecules-09-00650]\].

Whereas this research field provided many new insights during the last two decades, one has to emphasize that no complete trafficking pathway for any K~IR~ channel protein has been deciphered in detail yet. Furthermore, most of our current knowledge is derived from ectopic expressions systems rather than human native tissue or cells. Currently, we cannot exclude that K~IR~ subtype and/or tissue specific pathways exist. The observations that several diseases associate with K~IR~ channel trafficking malfunction might help us to further understand K~IR~ protein trafficking processes in their natural environments in vivo.

4. Diseases and Syndromes Associated with K~IR~ Channel Dysfunction {#sec4-biomolecules-09-00650}
===================================================================

A number of human diseases associate with mutations in K~IR~ channels, as indicated in [Table 1](#biomolecules-09-00650-t001){ref-type="table"}. Bartter syndrome type II is a salt-losing nephropathy resulting in hypokalemia and alkalosis associated with loss-of-function mutations in K~IR~1.1 channel proteins. K~IR~1.1 channels are essential for luminal extrusion of K^+^ in the thick ascending limb of Henle's loop, thereby permitting continued activity of the NKCC2 cotransporter important for sodium resorption \[[@B33-biomolecules-09-00650]\]. Loss-of-function in K~IR~2.1 causes Andersen--Tawil syndrome characterized by periodic skeletal muscle paralysis, developmental skeletal abnormalities, as well as biventricular tachycardia with or without the presence of long QT. On the other hand, K~IR~2.1 gain-of-function mutations result in cardiac phenotypes, atrial fibrillation and short QT syndrome, explained by increased repolarization capacity and thus shortened cardiac action potentials \[[@B34-biomolecules-09-00650],[@B35-biomolecules-09-00650]\]. Thyrotoxic hypokalemic periodic paralysis associated with K~IR~2.6 loss-of-function mutations affect skeletal muscle excitability under thyrotoxic conditions \[[@B36-biomolecules-09-00650]\]. Keppen--Lubinsky syndrome is an extremely rare condition associated with K~IR~3.2 gain-of-function mutations. Its phenotype encompasses lipodystrophy, hypertonia, hyperreflexia, developmental delay and intellectual disability \[[@B37-biomolecules-09-00650],[@B38-biomolecules-09-00650]\]. Familial hyperaldosteronism type III is associated with loss-of-function mutations in K~IR~3.4 channel proteins. The disease is characterized by early onset of severe hypertension and hypokalemia. Mutant K~IR~3.4 channels lack potassium specificity and the resulting inflow of Na^+^ and accompanying cell depolarization of zona glomerulosa cells increases intracellular Ca^2+^ concentrations, which activates transcription pathways that raise aldosterone production \[[@B39-biomolecules-09-00650]\]. Loss-of-function mutations in K~IR~3.4 associate with long QT syndrome 13, which indicates that these acetylcholine activated channels, mostly known from nodal tissues, also play a role in ventricular repolarization processes \[[@B40-biomolecules-09-00650]\]. EAST (epilepsy, ataxia, sensorineural deafness, tubulopathy)/SeSAME syndrome is a salt-losing nephropathy combined with severe neurological disorders. The disease associated loss-of-function mutations in K~IR~4.1 channels expressed in the distal convoluted tubule, result in hypokalemic metabolic acidosis. Impaired K~IR~4.1 function in glial cells will increase neural tissue potassium levels giving rise to neuron depolarization, whereas reduced potassium concentration in the endolymph affect cochlear hair cell function \[[@B41-biomolecules-09-00650]\]. Cantú syndrome results from gain-of-function of I~KATP~ channels, either due to mutation in K~IR~6.1 or the SUR2 subunits. Many of these mutations decrease the sensitivity of the channel to ATP-dependent closure \[[@B42-biomolecules-09-00650]\]. Insulin release by pancreatic beta-cells is regulated by their membrane potential and L-type Calcium channel activity. Depolarization activates Ca^2+^ influx inducing insulin release from intracellular stores into the extracellular fluid. Loss-of-function mutations in K~IR~6.2 result in membrane depolarization and thus insulin release and associate with hyperinsulism and hypoglycemia. Gain-of-function mutations on the other hand impair insulin release and associate with different forms of diabetes \[[@B43-biomolecules-09-00650]\]. K~IR~7.1 channels are expressed in the apical membrane of retinal pigmented epithelial cells and contribute to K^+^ homeostasis in the subretinal space. Loss-of-function mutations in K~IR~7.1 associate with retinal dysfunction observed in Lever congenital amaurosis type 16 and Snowflake vitreoretinal degeneration \[[@B44-biomolecules-09-00650]\].

In many of the above-mentioned diseases, loss-of-function has been associated with aberrant trafficking, most likely forward trafficking. Nonetheless, enhanced backward trafficking or impaired plasma-membrane anchoring cannot be excluded. However, most gain-of-function mutations are likely not related to trafficking abnormalities. Loss-of-specificity mutations, as seen in some K~IR~3.4 mutations, neither result from trafficking issues.

5. K~IR~ Protein Alignment of Trafficking Associated Disease Mutations {#sec5-biomolecules-09-00650}
======================================================================

In order to identify potential protein domains associated with K~IR~ trafficking defects in human disease, we aligned all K~IR~ isoforms and highlighted residues (in red) of which the mutations are experimentally proven to associate with trafficking defects ([Figure 3](#biomolecules-09-00650-f003){ref-type="fig"}, [Supplementary Figure S1](#app1-biomolecules-09-00650){ref-type="app"}). Furthermore, additional mutations in other K~IR~ isoforms at homologues positions, but currently not related to impaired trafficking, are indicated ([Supplementary Figure S1](#app1-biomolecules-09-00650){ref-type="app"}, in green). Trafficking associated mutations are found dispersed along the protein sequence, with one "hotspot" in the G-loop and adjacent C-terminal region, and one "hotspot" in and around transmembrane domain 1. Additionally, from a structural point of view, there is another "hotspot" at the immunoglobulin-like domain (IgLD), which is described in [Section 6.1](#sec6dot1-biomolecules-09-00650){ref-type="sec"}.

5.1. C-Terminal Trafficking Mutation Hotspot {#sec5dot1-biomolecules-09-00650}
--------------------------------------------

[Figure 4](#biomolecules-09-00650-f004){ref-type="fig"} depicts the alignment of the C-terminal hotspot, having ten trafficking associated mutations/deletions located in K~IR~1.1, K~IR~2.1 and/or K~IR~6.2 over a stretch of 44 residues. This region also covers the filamin A interaction domain of K~IR~2.1 (307--326) \[[@B32-biomolecules-09-00650]\]. The loss-of-function E282K mutation in K~IR~6.2 is associated with congenital hyperinsulinism \[[@B45-biomolecules-09-00650]\]. This mutation affects normal function of a highly conserved di-acidic ER exit signal (DxE) that prevents mutant channels to enter ER exit sites, which thus fail to traffic to the plasma membrane \[[@B45-biomolecules-09-00650]\]. The Andersen--Tawil loss-of-function K~IR~2.1 mutation V302M is located in the G-loop and displays intracellular, but no plasma-membrane expression, upon transfection of HEK293 cells \[[@B46-biomolecules-09-00650]\]. However, Ma et al., \[[@B47-biomolecules-09-00650]\] demonstrated that the K~IR~2.1 V302M mutation does not affect trafficking. The Bartter syndrome associated loss-of-function A306T mutation in K~IR~1.1 is also located in the G-loop. Its expression in the *Xenopus* oocyte membrane is strongly reduced compared to wildtype channels \[[@B48-biomolecules-09-00650]\]. At homologues positions, disease causing mutations have been found in K~IR~2.1 \[[@B49-biomolecules-09-00650]\] and K~IR~6.2 \[[@B50-biomolecules-09-00650]\] whose cause for loss- and gain-of-function, respectively, is unknown but may be caused by trafficking abnormalities. Hyperinsulinism associated K~IR~6.2 R301H/G/C/P loss-of-function mutations are located just C-terminal from the G-loop domain. These mutants display reduced surface expression when expressed in COSm6 or INS cells \[[@B51-biomolecules-09-00650]\]. Interestingly, however, the R301A mutation displays normal expression at the plasma membrane \[[@B51-biomolecules-09-00650]\]. At homologues positions, mutations have also been found in K~IR~1.1 \[[@B52-biomolecules-09-00650]\] and K~IR~4.1 \[[@B53-biomolecules-09-00650]\].

By use of homology comparison and structure guided mutagenesis, a common Golgi-export signal patch was found to be formed by a C-terminal stretch of hydrophobic residues and basic residues from the N-terminus \[[@B16-biomolecules-09-00650],[@B17-biomolecules-09-00650]\]. The C-terminal stretch sequence is formed by residues SYxxxEIxW indicated in [Figure 4](#biomolecules-09-00650-f004){ref-type="fig"}. Two Bartter syndrome associated K~IR~1.1 (Y314C; L320P) and two Andersen--Tawil syndrome associated K~IR~2.1 (delSY; W322S) confirmed trafficking mutations have been described in this region \[[@B46-biomolecules-09-00650],[@B48-biomolecules-09-00650],[@B54-biomolecules-09-00650]\]. Interestingly, the W residue is not conserved in the K~IR~7.1 channel protein, which may indicate K~IR~ subtype specific use of the entire Golgi-export signal motif. Two additional K~IR~1.1 mutations leading to altered trafficking, R324L and F325C have been located directly C-terminal from the Golgi-export signal stretch \[[@B48-biomolecules-09-00650],[@B52-biomolecules-09-00650]\].

Fallen et al. \[[@B55-biomolecules-09-00650]\] showed that mutations A198T and Y314C in the IgLD, located in the CTD of K~IR~1.1, are associated with defects in channel trafficking and gating, see also [Section 6.1](#sec6dot1-biomolecules-09-00650){ref-type="sec"}. Y314C is present within the C-terminal trafficking mutation hotspot and part of the Golgi-export signal as discussed above. If incorrectly folded, the aberrant K~IR~1.1 proteins will enter the endoplasmic-reticulum-associated protein degradation pathway \[[@B56-biomolecules-09-00650]\].

5.2. Transmembrane Region 1 Mutation Hotspot {#sec5dot2-biomolecules-09-00650}
--------------------------------------------

[Figure 5](#biomolecules-09-00650-f005){ref-type="fig"} depicts the alignment of transmembrane domain 1 and adjacent sequences, containing 15 trafficking associated mutations located in K~IR~1.1, K~IR~2.1, K~IR~3.4 or K~IR~4.1. Three mutations in the cytoplasmic domain, positioned just in front of the first transmembrane region in K~IR~1.1 (T71M, V72M and D74Y), have been demonstrated to strongly decrease plasma-membrane expression and mutant channels were retained in the cytoplasm \[[@B48-biomolecules-09-00650],[@B57-biomolecules-09-00650]\]. However, membrane expression of T71M in *Xenopus* oocytes could be rescued by increasing the amount of injected RNA, in contrast to the other two mutations. For K~IR~1.1 T71M, mutations at the homologues positions were found in K~IR~2.1 (T75) \[[@B58-biomolecules-09-00650],[@B59-biomolecules-09-00650],[@B60-biomolecules-09-00650],[@B61-biomolecules-09-00650],[@B62-biomolecules-09-00650]\] and K~IR~6.2 (T62) \[[@B63-biomolecules-09-00650],[@B64-biomolecules-09-00650]\] associated with Andersen--Tawil syndrome and Familial hyperinsulinemic hypoglycemia type 2, respectively. The K~IR~2.1 T75R protein was observed at the plasma membrane upon overexpression in HL1 cells \[[@B60-biomolecules-09-00650]\]. Moreover, T75A, T75R and T75M channel proteins were also expressed at the plasma membrane in *Xenopus* oocytes, HEK293 or COS-7 cells \[[@B58-biomolecules-09-00650],[@B61-biomolecules-09-00650],[@B65-biomolecules-09-00650]\]. In contrast, impaired plasma-membrane localization of T75M K~IR~2.1 was observed in HEK293 cells in another study \[[@B62-biomolecules-09-00650]\]. Two K~IR~2.1 mutations, i.e., D78G and D78Y, are at the equivalent position as D74 in K~IR~1.1, and also D78Y was found at the plasma membrane in *Xenopus* oocytes and HEK293 cells \[[@B59-biomolecules-09-00650],[@B65-biomolecules-09-00650],[@B66-biomolecules-09-00650]\]. These comparisons indicate that findings on plasma-membrane expression may be influenced by the degree of overexpression and cell type. K~IR~2.1 T75 and D78 residues are positioned on the hydrophilic side of the slide helix that interacts with the cytoplasmic domain. The D78Y mutation disrupts this interaction \[[@B65-biomolecules-09-00650]\].

Trafficking associated mutations in the highly conserved transmembrane region 1 are described for K~IR~1.1, K~IR~2.1 and K~IR~4.1 \[[@B46-biomolecules-09-00650],[@B48-biomolecules-09-00650],[@B67-biomolecules-09-00650],[@B68-biomolecules-09-00650],[@B69-biomolecules-09-00650]\]. Expression of K~IR~1.1 Y79H in the *Xenopus* oocyte plasma-membrane increases upon increasing the amount of RNA injection by ten-fold \[[@B48-biomolecules-09-00650]\]. The K~IR~2.1 L94P, Δ95-98 and K~IR~4.1 G77R channel proteins localize intracellularly \[[@B46-biomolecules-09-00650],[@B68-biomolecules-09-00650],[@B69-biomolecules-09-00650]\]. The molecular mechanisms by which these mutations affect normal trafficking remain to be solved. However, interactions with wildtype subunits appear not to be affected and may explain the dominant negative properties of these mutations. The familial sinus node disease associated K~IR~3.4 W101C gain-of-function mutation is located at a position homologues to K~IR~2.1 W96 \[[@B70-biomolecules-09-00650]\]. In an ectopic expression system, the K~IR~3.4 W101C protein is expressed at the plasma membrane, however it decreased surface expression of K~IR~3.1 when co-expressed \[[@B70-biomolecules-09-00650]\].

Confirmed trafficking associated mutations C-terminal from the transmembrane region 1 are found in K~IR~1.1 and K~IR~3.4 \[[@B48-biomolecules-09-00650],[@B71-biomolecules-09-00650],[@B72-biomolecules-09-00650]\]. K~IR~1.1 D108H and V122E mutants did not display membrane staining in *Xenopus* oocytes or HEK293 cells \[[@B48-biomolecules-09-00650]\]. When comparing single channel characteristics with macroscopic currents, it was concluded that loss-of-function of K~IR~1.1 N124K was caused by a reduction of functional channels at the plasma membrane \[[@B71-biomolecules-09-00650]\]. The K~IR~3.4 R115W mutation was obtained from aldosterone-producing adenoma linked to hyperaldosteronism, and displayed decreased plasma-membrane expression in HEK293 cells \[[@B72-biomolecules-09-00650]\]. A mutation, at a position homologues to V122 in K~IR~1.1, has also been identified in K~IR~2.1 \[[@B59-biomolecules-09-00650]\].

5.3. N-Terminal Golgi-Export Patch, K~IR~2.x ER Export, and K~IR~6.x ER Exit and Retention Signals {#sec5dot3-biomolecules-09-00650}
--------------------------------------------------------------------------------------------------

As indicated above, the so-called Golgi-export patch consists of interaction of a C-terminal and N-terminal domain \[[@B16-biomolecules-09-00650],[@B17-biomolecules-09-00650]\]. Mutations in the C-terminal domain have been found (see [Section 5.1](#sec5dot1-biomolecules-09-00650){ref-type="sec"}). However, only few mutations have been described in the N-terminal part (K~IR~2.1 G52V; K~IR~2.6 R43C) that result in reduced plasma membrane expression by hampering Golgi export \[[@B73-biomolecules-09-00650],[@B74-biomolecules-09-00650]\]. Thus far, no mutations of residue R20 in K~IR~2.3, which is required for Golgi export \[[@B17-biomolecules-09-00650]\], or at the homologues position in any other K~IR~ channel protein have been identified.

K~IR~2.x channels share a short C-terminal ER-export signal (FCYENE) \[[@B10-biomolecules-09-00650],[@B11-biomolecules-09-00650]\]. K~IR~3.2 contains N-terminal (DQDVESPV) and C-terminal (ELETEEEE) ER-export signals, whereas K~IR~3.4 possesses the N-terminal NQDMEIGV ER-export signal \[[@B12-biomolecules-09-00650]\]. Remarkable, we did not encounter any trafficking associated mutations in any of these domains. In contrast, one mutation (E282K) was present in the di-acidic ER exit signal of K~IR~6.2 as discussed in [Section 5.1](#sec5dot1-biomolecules-09-00650){ref-type="sec"}. K~IR~6.x and SURx channel proteins contain a C-terminal ER-retention signal (RKR) \[[@B13-biomolecules-09-00650]\]. Upon channel assembly, retention signals from both proteins are shielded, supporting subsequent ER-export. No trafficking associated mutations were found in these retention signals in K~IR~6.x channel proteins.

We therefore propose that mutations in Golgi-export domains have more severe clinical implications than mutations in ER-export/retention signals.

6. Structural Mapping of Trafficking Defect Causing Mutants {#sec6-biomolecules-09-00650}
===========================================================

Disease causing mutations associated with trafficking deficiencies were mapped onto the common structural scaffold of a recently published high resolution K~IR~2.2 structure \[[@B75-biomolecules-09-00650]\]. As illustrated in [Figure 6](#biomolecules-09-00650-f006){ref-type="fig"}, mutations are globally distributed.

A group of mutations clusters at regions important for channel gating, including the PIP~2~ binding site (T71M, V72E, D74Y and Y79H in K~IR~1.1), the helix bundle crossing gate (A167V in K~IR~4.1; R162W/Q in K~IR~7.1) \[[@B76-biomolecules-09-00650],[@B77-biomolecules-09-00650],[@B78-biomolecules-09-00650]\], as well as the G-loop gate (V302M, K~IR~2.1). It can be expected that these mutations have strong effects on the conformational equilibrium, thereby impairing normal protein function. It is likely that these mutants lead to structurally less-stable proteins, thereby making them more susceptible for degradation. Interestingly, 58% of the currently known trafficking defect causing mutations in K~IR~ channel proteins cluster in the cytoplasmic domain, which has been shown to be crucial for efficient folding in K~v~AP channels \[[@B79-biomolecules-09-00650]\].

Another cluster of mutants (D108H, V122E and N124K in K~IR~1.1; R115W in K~IR~3.4; C140R in K~IR~4.1) is found on surface exposed loops of the channel. Except for C140R in K~IR~4.1 \[[@B68-biomolecules-09-00650]\], which is part of a disulfide bridge \[[@B80-biomolecules-09-00650]\], none of the mutations causes changes in polarity or is at important structural motifs, leaving it unclear why these mutants cause trafficking defects.

Mutations G77R in K~IR~4.1 \[[@B68-biomolecules-09-00650]\] and C101R in K~IR~2.1, located on the membrane facing side and near the center of transmembrane helix M1, cause changes in the helical properties and hydrophobicity. It is thus conceivable that they severely affect helical stability and possibly membrane insertion. It has been shown in numerous studies that the cost for exposing arginine to lipid hydrocarbons is prohibitively high \[[@B81-biomolecules-09-00650]\]. Interestingly, none of the identified disease mutations is located at the interface between subunits.

6.1. Structure-Based Hotspot in the IgLD Beta Barrel of the CTD {#sec6dot1-biomolecules-09-00650}
---------------------------------------------------------------

Two antenatal Bartter syndrome loss-of-function mutations A198T and Y314C, located in the IgLD have been shown to impair forward trafficking and gating of K~IR~1.1 channels, possibly influencing the core stability of this domain \[[@B55-biomolecules-09-00650]\]. Interestingly, a trafficking affecting mutation in a homologous position to K~IR~1.1 A198 has been identified in K~IR~2.6 (A200P) \[[@B74-biomolecules-09-00650]\], and another mutation thus far not associated with trafficking has been identified in K~IR~6.2 (A187V). As shown in [Figure 7](#biomolecules-09-00650-f007){ref-type="fig"}, quite a large number of disease causing mutations, including A306T (implicated in trafficking) \[[@B48-biomolecules-09-00650]\], R311W and L320P in K~IR~1.1 (no data on trafficking), S314-Y315 deletion in K~IR~2.1 (implicated in trafficking) \[[@B16-biomolecules-09-00650]\], E282K (prevents ER-export and surface expression of the channel) \[[@B45-biomolecules-09-00650]\] or L241P in K~IR~7.1 (implicated in trafficking) \[[@B78-biomolecules-09-00650]\], have been reported in the literature. This, as well as previous work \[[@B55-biomolecules-09-00650]\], suggests that this structural motif might be a crucial hotspot implicated in trafficking of K~IR~ channels.

7. Conclusions {#sec7-biomolecules-09-00650}
==============

Mutations in K~IR~ potassium ion channels associate with a variety of human diseases in which electrophysiological and potassium homeostasis aberrations are explaining etiology. Many of the mutations associate with abnormal, mostly decreased forward, ion channel trafficking. Trafficking associated mutations are present throughout the primary sequence, but they concentrate in cytoplasmic domains in which channel structures involved in Golgi-export are clinically more important than ER-export regions. Another group of mutations are found in regions important for gating and most likely affect protein folding and stability. Therefore, mutation associated K~IR~ trafficking defects are likely caused by 1) defective interaction with the trafficking machinery due to mutations in specific trafficking motifs, and 2) channel misfolding, destabilization and subsequent endoplasmic-reticulum-associated protein degradation due to mutations in residues important for channel structure.

The following are available online at <https://www.mdpi.com/2218-273X/9/11/650/s1>, Figure S1: K~IR~1-7 sequence alignment.

###### 

Click here for additional data file.
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![Two opposing domains of the K~IR~ channel with structural common features highlighted. The membrane is indicated by dotted lines. The selectivity filter (SF) is highlighted by a dotted box. Ions inside the SF are shown as green spheres. Residues E138 and R148 (K~IR~2.1) are shown as spheres.](biomolecules-09-00650-g001){#biomolecules-09-00650-f001}

![Schematic representation of intracellular trafficking pathways of K~IR~ channels. TGN, trans-Golgi network; MVB, multivesicular body.](biomolecules-09-00650-g002){#biomolecules-09-00650-f002}

![Schematic representation of inward rectifier channels (K~IR~1--7) sequence alignment. Red: mutations associated with aberrant trafficking; mutation hotspots are boxed. Orange: transmembrane domain; blue: K~IR~ protein sequence; gray: sequence gap.](biomolecules-09-00650-g003){#biomolecules-09-00650-f003}

![K~IR~1--7 sequence alignment of the C-terminal mutation hotspot. Red: Mutations associated with aberrant trafficking; Green: Residues whose mutations are currently not related to impaired trafficking. Numbers at the right refer to the last amino-acid residue in the respective sequence shown. Conserved residues among all K~IR~ members are shaded gray. Locations of the di-acidic ER exit, G-loop and the Golgi-Export signal sequence (see text) are indicated below the alignment.](biomolecules-09-00650-g004){#biomolecules-09-00650-f004}

![K~IR~1--7 sequence alignment of the transmembrane domain 1 mutation hotspot. Red: mutations associated with aberrant trafficking; Green: residues whose mutations are currently not related to impaired trafficking. Numbers at the right refer to the last amino-acid residue in the respective sequence shown. Conserved residues among all K~IR~ members are shaded gray. Location of the transmembrane domain 1 (orange) is indicated below the alignment.](biomolecules-09-00650-g005){#biomolecules-09-00650-f005}

![Structural mapping of trafficking mutants mapped on the K~IR~2.2 structure. For clarity reasons, only three of the four subunits are shown in side view, with the disease associated mutations highlighted in one subunit only. Mutations of different K~IR~ channel family members are color-coded and shown as spheres of their respective Cα atoms. Deletions are indicated by colored regions on the secondary structure elements.](biomolecules-09-00650-g006){#biomolecules-09-00650-f006}

![Structure-based IgLD hotspot (mapped on the K~IR~2.2 structure), with disease associated mutations highlighted. Mutations of the different family members are color-coded and shown as spheres of their respective Cα atoms.](biomolecules-09-00650-g007){#biomolecules-09-00650-f007}
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###### 

Human diseases associated with abnormal K~IR~ channel function.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Protein    Gene       Syndrome/Disease Character (OMIM)^1^                 Main Affected System(s)                                                                               Recent Review
  ---------- ---------- ---------------------------------------------------- ----------------------------------------------------------------------------------------------------- ---------------------------------------------------------------
  K~IR~1.1   *KCNJ1*    Bartter syndrome, type 2 (241200)                    Kidney; head; face; ear; eye; vascular; gastrointestinal; skeleton; skeletal muscle; CNS; platelets   \[[@B33-biomolecules-09-00650]\]

  K~IR~2.1   *KCNJ2*    Andersen syndrome (170390)\                          Head; face; ear; eye; teeth; heart; skeleton; CNS                                                     \[[@B34-biomolecules-09-00650],[@B35-biomolecules-09-00650]\]
                        Familial atrium fibrillation 9 (613980)\                                                                                                                   
                        Short QT syndrome 3 (609622)                                                                                                                               

  K~IR~2.2   *KCNJ12*   Non-described                                                                                                                                              

  K~IR~2.3   *KCNJ4*    Non-described                                                                                                                                              

  K~IR~2.4   *KCNJ14*   Non-described                                                                                                                                              

  K~IR~2.6   *KCNJ18*   Thyrotoxic hypokalemic periodic paralysis (613239)   Cardiovascular; skeletal muscle; CNS; eye                                                             \[[@B36-biomolecules-09-00650]\]

  K~IR~3.1   *KCNJ3*    Non-described                                                                                                                                              

  K~IR~3.2   *KCNJ6*    Keppen--Lubinsky Syndrome (614098)                   CNS; head; skin; skeleton; eye, face                                                                  No review available

  K~IR~3.3   *KCNJ9*    Non-described                                                                                                                                              

  K~IR~3.4   *KCNJ5*    Familial hyperaldosteronism 3 (613677)\              Cardiovascular; kidney; skeletal muscle                                                               \[[@B39-biomolecules-09-00650],[@B40-biomolecules-09-00650]\]
                        Long QT syndrome 13 (613485)                                                                                                                               

  K~IR~4.1   *KCNJ10*   Digenic enlarged vestibular aqueduct (600791)\       Ear (hearing); vascular; kidney; CNS                                                                  \[[@B41-biomolecules-09-00650]\]
                        EAST/SESAME syndrome (612780)                                                                                                                              

  K~IR~4.2   *KCNJ15*   Non-described                                                                                                                                              

  K~IR~5.1   *KCNJ16*   Non-described                                                                                                                                              

  K~IR~6.1   *KCNJ8*    Cantú syndrome (239850)                              Head; face; cardiovascular; skeleton; hair; CNS                                                       \[[@B42-biomolecules-09-00650]\]

  K~IR~6.2   *KCNJ11*   Transient neonatal diabetes mellitus 3 (610582)\     Pancreas (beta-cells); CNS                                                                            \[[@B43-biomolecules-09-00650]\]
                        Permanent neonatal diabetes with or\                                                                                                                       
                        without neurologic features (606176)\                                                                                                                      
                        Familial hyperinsulinemic hypoglycemia 2 (601820)\                                                                                                         
                        Maturity-onset diabetes of the young 13 (616329)\                                                                                                          
                        Susceptible to diabetes mellitus 2 (125853)                                                                                                                

  K~IR~7.1   *KCNJ13*   Leber congenital amaurosis 16 (614186)\              Eye (retina)                                                                                          \[[@B44-biomolecules-09-00650]\]
                        Snowflake vitreoretinal degeneration (193230)                                                                                                              
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

OMIM^1^: OMIM^®^---Online Mendelian Inheritance in Man^®^ <https://omim.org> assessed on 24 July 2019, CNS, central neural system.

[^1]: These authors contributed equally to this work.
